Unaudited Financial Results (standalone and consolidated) for the quarter ended June 30, 2026
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 18 Jul 2026, 04:46 PM IST · BSE ID: 54c3ffcb-b144-4d1e-8aed-f7176d2949d6
View Original BSE Filing (PDF)
💡
In Simple Terms
Rossari Biotech's board approved quarterly financial results and employee stock options, and conducted an internal overseas subsidiary restructuring.
🤖 AI Summary
- Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
- Grant of 4000 Stock Options approved under Rossari Employee Stock Option Plan - 2019 at Rs. 531 per option.
- Allotment of 2500 Equity Shares of Rs. 2/- each to grantees upon exercise of ESOP 2019 options.
- Issued and paid-up equity share capital increased to Rs. 11,07,88,232, comprising 55394116 Equity Shares of Rs. 2/- each.
- Transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. approved for group restructuring.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Stock Options Granted
4000 Options
Exercise Price per Option
Rs. 531
Number of Equity Shares Allotted
2500 Equity Shares
Face Value per Equity Share
Rs. 2/-
Issued and Paid-up Equity Share Capital (after allotment)
Rs. 11,07,88,232
Total Equity Shares (after allotment)
55394116 Equity Shares
🏢 How This Affects the Company
The internal group restructuring aims to simplify overseas regulatory reporting by consolidating all overseas subsidiaries under Rossari (Singapore) Pte. Ltd., establishing a common holding platform.
The allotment of 2500 equity shares increases the issued and paid-up equity share capital to Rs. 11,07,88,232. The internal transfer of shareholding between wholly-owned subsidiaries is not expected to materially impact consolidated financials.
The transfer of Rossari International Limited to Rossari (Singapore) Pte. Ltd. streamlines the company's overseas operational structure for reporting.
The internal restructuring of overseas subsidiaries aims to simplify regulatory reporting, which could potentially reduce compliance complexities, but remains subject to required approvals from Saudi Arabian authorities.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders' equity is minimally diluted by the allotment of 2500 new equity shares, increasing total shares to 55394116. Employees granted options will be affected by future vesting and exercise.
🔍
Management Signal
Management intends to align employee incentives through ESOPs and to streamline the structure of its overseas operations for simplified reporting.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Release of detailed unaudited financial results for the quarter ended June 30, 2026.
Announcement of completion and regulatory approvals for the overseas subsidiary transfer.
Future disclosures on ESOP vesting and exercise activities.
LOW RISK
The filing reports routine Board approvals and an internal restructuring with no stated material financial impact.
💡 Investor Takeaway
Rossari Biotech's Board approved Q1 FY27 unaudited financial results and granted 4000 ESOP options at Rs. 531 per option. 2500 Equity Shares of Rs. 2/- each were allotted, increasing paid-up capital to Rs. 11,07,88,232. An internal overseas subsidiary restructuring was also approved.
⚖️ Strengths & Concerns
✅ Positives
- Grant of 4000 Stock Options under ESOP 2019 to eligible employees aligns employee incentives with company performance.
- Internal group restructuring to consolidate overseas subsidiaries under a single platform simplifies overseas regulatory reporting.
⚠️ Concerns
- No specific financial performance figures were provided in the filing for the quarter ended June 30, 2026.
- The transfer of Rossari International Limited to Rossari (Singapore) Pte. Ltd. is subject to execution of a Share Purchase Agreement and Saudi Arabian approvals.
❓ Frequently Asked Questions
What decisions did Rossari Biotech's Board make on July 18, 2026?
The Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, granted 4000 Stock Options under ESOP 2019, allotted 2500 Equity Shares, and approved the transfer of Rossari International Limited to Rossari (Singapore) Pte. Ltd.
How many Stock Options were granted by Rossari Biotech, and at what price?
Rossari Biotech granted 4000 Stock Options under ESOP 2019. The exercise price for these options has been determined as Rs. 531 per Option.
What is the new issued and paid-up equity share capital of Rossari Biotech after the recent allotment?
Following the allotment of 2500 Equity Shares of Rs. 2/- each, the issued and paid-up equity share capital of Rossari Biotech Limited stands at Rs. 11,07,88,232, consisting of 55394116 Equity Shares of Rs. 2/- each.
What is the purpose of transferring Rossari International Limited to Rossari (Singapore) Pte. Ltd.?
The transfer is part of an internal group restructuring to bring all overseas subsidiaries under a single existing overseas investment subsidiary, aiming to simplify overseas regulatory reporting into a single line.
Questions based on this BSE filing only. For information purposes.